Loading clinical trials...
Loading clinical trials...
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of Miami
NCT02800486 · Glioblastoma, Anaplastic Astrocytoma, and more
NCT05839379 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and more
NCT00083512 · Glioblastoma Multiforme
NCT07100730 · Neoplastic Disease, Glioblastoma, and more
NCT05281731 · Glioblastoma, Glioblastoma Multiforme
Jackson Memorial Hospital
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions